Lexus offers three distinct new models of its eighth-gen ES sedan, with two battery electric models and a hybrid. The BEVs are out now, while the hybrid bows next month. Prices go from $48,895 for the ...

The Lexus ES has always been a rational luxury car. Since its 1989 debut, it has served buyers who wanted the refinement, quietness, reliability, and dealership experience of a premium brand without ...

For decades, the Lexus ES has existed in a comfortable little bubble. Buyers loved it because it was quiet, reliable, spacious, and almost aggressively committed to not upsetting anyone. It wasn’t ...

“The more things change, the more they stay the same.” This well-known aphorism, taken from the original French (“Plus ça change…”) could be well applied to the eighth-generation Lexus ES. Sure, there ...

Although Lexus is no stranger to sporty models, this luxury brand made its name on quiet, plush sedans that prioritize refinement above all else. And the ES is the one that has persisted. This comfy ...

For the first time, the ES hybrid is available with an all-wheel-drive option. Lexus says the hybrid version of the eighth-generation ES is on track for its expected June arrival, when it will join ...

Unveiled in April 2025 for the 2026 model year in Shanghai, the eighth generation of the Lexus ES is the first ES to be sold with battery-electric options. The 350e currently retails at $48,895 ...

Git isn't hard to learn, and when you combine Git and GitHub, you've just made the learning process significantly easier. This two-hour Git and GitHub video tutorial shows you how to get started with ...

A new test firmware build from Blackmagic Design extends phase-detection autofocus to the PYXIS 6K, following its introduction on the Cinema Camera 6K last year. The latest beta version of Blackmagic ...

View post: Mazda Says The SUV Boom Hasn’t Peaked Yet The 2026 Lexus ES starts under $50,000, undercutting rival luxury sedans in price. The entry-level EV is cheaper than the hybrid, an uncommon ...

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an ...

Pyxis secured S$13 million in the first close of its S$18 million growth funding round, reflecting strong investor confidence in its vessel technology, commercial traction, and regional growth ...